(Reuters) – Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday.
Jimenez’ comments echoed concerns expressed on Thursday by U.S. Federal Reserve Chair Janet Yellen, who said the outlook in emerging markets including China have led to volatility.
Despite the increasing risks, Jimenez said the Swiss company was not pulling back from emerging markets, rather relying on the strength of generics in China to drive business growth.
“So we are not pulling back. We’re in these markets for the long term. We are going to live through the volatility,” he said.
“We have seen a bit of a slowdown in emerging markets particularly China but in our business that means moving from mid-double digit growth rates to now in the mid-single digit growth rates,” he added. “If you think about the global healthcare market maybe growing at 2 or 3 percent this is still incremental growth.”
Novartis shares fell further after Jimenez’ comments, and were down 1.1 percent at 0900 GMT.
Novartis was still digesting acquisitions including from its $20 billion asset swap last year with GlaxoSmithKline, which bolstered the Basel-based company’s position in cancer drugs, among others.
Jimenez did not rule out further acquisitions.
“We’re looking at everything that’s out there,” he said. “The reason why Novartis hasn’t moved is that assets are very expensive right now and I think we’re going to hold our powder, we’re going to see what happens in the markets.” ($1 = 0.9573 Swiss francs) (Reporting by John Miller; Editing by Joshua Franklin and Susan Fenton)
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
